A look at earnings from the view of macro-economists and market technicians
A bottom-up view of earnings from professional equity analysts
Documentation, research, and support for the information provided
Sign in using:
Don't have an account?
Earnings Whisper ®
2nd Quarter June 2021
Revenue: $164.16 Mil
After the close
Monday, May 3, 2021
Myriad Genetics to Update Progress on Transformation Plan and Growth Initiatives, Share Long-Term Financial Outlook at 2021 Investor Day
What do you expect when MYGN reports earnings?
Where is MYGN's stock price going from here?
Myriad Genetics, Inc. is focused on revolutionizing patient care through the discovery, development and marketing of transformative molecular diagnostic tests that address pressing clinical needs across multiple medical specialties. Myriad is the pioneer and leader in molecular diagnostics, offering innovative products that transform patients' lives. These products include leading molecular diagnostic tests for hereditary cancer, urological cancer, lung cancer, autoimmune disorders and other diseases. Myriad has invested heavily in educating patients and healthcare professionals about the role genes and proteins play in disease. Myriad's hereditary cancer genetic testing, which helps healthcare professionals better manage and tailor medical care. Myriad is expanding their reach and increasing their impact on patient care by introducing new molecular diagnostic and companion diagnostic tests for a growing number of diseases.